The federal body's appeal to COVID vaccine makers comes at a time when the United States is moving to a commercial marketplace for COVID products from government purchases in the early years of the pandemic. In a letter to vaccine manufacturers Pfizer/BioNTech, Moderna and Novavax, HHS said it expects them to prepare for an ample supply for the 2023-24 fall vaccination campaign, and remain prepared to support any potential surges in demand and evolving COVID-19 situations. While Moderna and Pfizer have not settled on a price, the companies are planning to target a range of commercial price of $110 to $130 a dose for their vaccines.
Related Keywords
Bengaluru , Karnataka , India , Bhanvi Satija , Shinjini Ganguli , Drug Administration , Us Department Of Health , Human Services , Centers For Disease , Reuters , Disease Control , Vaccine Manufacturers , S Department Of Health And Human Services , Commercial Price , Novavax , Covid , Covid Vaccine ,
comparemela.com © 2020. All Rights Reserved.